[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572693":3},{"organization":4,"armGroups":7,"interventions":45,"overallOfficials":11,"centralContacts":11,"locations":53,"responsibleParty":72,"collaborators":11,"id":74,"slug":11,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":11,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":11,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":11,"overallStatus":56,"whyStopped":11,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8,15,18,21,24,27,30,33,36,39,42],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort1","EXPERIMENTAL",null,[13,14],"Drug: DWP212525 XXmg","Drug: DWP212525 placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Cohort2",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Cohort3",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Cohort4",[13,14],{"label":25,"type":10,"description":11,"interventionNames":26},"Cohort5",[13,14],{"label":28,"type":10,"description":11,"interventionNames":29},"Cohort6",[13,14],{"label":31,"type":10,"description":11,"interventionNames":32},"Cohort7",[13,14],{"label":34,"type":10,"description":11,"interventionNames":35},"Cohort8",[13,14],{"label":37,"type":10,"description":11,"interventionNames":38},"Cohort9",[13,14],{"label":40,"type":10,"description":11,"interventionNames":41},"Cohort10",[13,14],{"label":43,"type":10,"description":11,"interventionNames":44},"Cohort 11",[13,14],[46,50],{"type":47,"name":48,"description":48,"armGroupLabels":49,"otherNames":11},"DRUG","DWP212525 XXmg",[43,9,40,16,19,22,25,28,31,34,37],{"type":47,"name":51,"description":51,"armGroupLabels":52,"otherNames":11},"DWP212525 placebo",[43,9,40,16,19,22,25,28,31,34,37],[54],{"facility":55,"status":56,"city":57,"state":11,"zip":58,"country":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Seoul National University Hospital","RECRUITING","Seoul","03080","South Korea",{"type":61,"coordinates":62},"Point",[63,64],126.9784,37.566,{"lat":64,"lon":63},[67],{"name":68,"role":69,"phone":70,"phoneExt":11,"email":71},"Seunghwan Lee","CONTACT","+220720694","leejh413@snu.ac",{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100572693",false,"NCT06736587","Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers","A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers","Inclusion Criteria:\n\n1. Healthy adult volunteers aged 19 to 55 years\n2. Those with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg\u002Fm2 to ≤ 30.0 kg\u002Fm2\n3. Received a sufficient explanation on this study\n4. Eligible as subjects in the study\n\nExclusion Criteria:\n\n1. History of diseases such as clinically significant disease of hepatobiliary\n2. Following conditions applicable to clinically significant acute or chronic infections or the past history confirmed via an interview\n3. Hemato-oncologic diseases, including malignant tumor diagnosis\n4. Past history of tuberculosis infection or confirmed tuberculosis in the IGRA test and chest X-ray test",true,"ALL","19 Years","55 Years",{"count":85,"type":86},84,"ESTIMATED","INTERVENTIONAL",[89],"PHASE1","The safety and tolerability of single and multiple administration of DWP212525",[92],"Autoimmune Diseases","2026-06-03",{"date":95,"type":96},"2026-06-08","ACTUAL",{"date":98,"type":96},"2024-12-10",{"date":100,"type":86},"2027-03-30",{"name":5,"class":6},1]